Advanced Contrast Agents Aim To Improve Cost, Convenience Of Cardiac Imaging
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Diagnosis of cardiovascular disease could become less costly and invasive if the alternatives to nuclear imaging and X-ray angiography that dominate the late-stage imaging agent pipeline live up to their promise.
You may also be interested in...
Guerbet Looks To Separate Dotarem In Crowded Contrast Agent Market
FDA advisory committee scheduled for Valentine’s Day is key test for Guerbet’s efforts to get its MRI imaging agent a wider indication than Bayer’s Gadavist.
CVT Plans Regadenoson NDA Submission As Cardiac Stress Agent For 2006
CV Therapeutics expects to wrap-up two Phase III trials of its selective A2A-adenosine receptor agonist regadenoson (CVT-3146) in the third and fourth quarters, in time for a 2006 NDA submission
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011